Long‐term remission in an aggressive <scp>C</scp>rooke cell adenoma of the pituitary , 18 months after discontinuation of treatment with temozolomide

Abstract

KEY CLINICAL MESSAGE: The clinical course of our patient, who sustained remission status for at least 18 months highlights the chance of long-term hormonal and tumor remission and demonstrates the efficacy and safety of discontinuation of temozolomide therapy. Prospective studies are required in order to define predictors of long-term remission of this promising therapeutic modality.